Abstract: The present invention pertains to the treatment of idiopathic thrombocytopenic purpura (ITP) employing pharmaceutical compositions containing a VLA-4 antagonist as active ingredient. The VLA-4 antagonists may be in form of chemical compounds or antibodies specifically blocking VLA-4 activity avoiding side-effects.
Abstract: The present invention relates to the field of myopathy and particularly to the treatment and/or prevention of inclusion body myositis (IBM). A composition is provided, which comprises as an active ingredient either growth hormone, a secretagogue thereof or a mixture thereof, to cure IBM or suppress the symptoms associated therewith.